



September 16, 2016

FunPep Co., Ltd.

## **Sumitomo Dainippon Pharma and FunPep Conclude Joint Research Agreement on Antibody-Inducing Peptides**

FunPep Co., Ltd. ("FunPep") (Headquarters: Ibaraki, Osaka; President & CEO: Akimitsu Hirai) announced today that it has entered into an agreement with Sumitomo Dainippon Pharma Co. ("DS Pharma") (Headquarters: Chuo-ku, Osaka; President & CEO: Masayo Tada) on September 15, 2016, to conduct joint research on antibody-inducing peptides against specific target molecules.

FunPep has been conducting research and development of antibody-inducing peptides using the STEP-UP platform technology based on joint research with Osaka University Graduate School of Medicine. Antibody-inducing peptides are peptide drug candidates designed to induce the body to produce antibodies that inhibit the action of target molecules. Through this collaboration with DS Pharma, FunPep will utilize DS Pharma's drug discovery know-how to create antibody-inducing peptides against specific target molecules.

FunPep will receive research funds from DS Pharma for use in this joint research project.